Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by (1,000)

Items 701–800 of 1,000

1. New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
   Katja Schlichtig, Lisa Cuba, Pauline Dürr, Laura Bellut, Norbert Meidenbauer, Frank Kunath, Peter Jürgen Goebell, Andréas Mackensen, Frank Dörje, Martin F. Fromm et al. · 2022 · Journal of Clinical Medicine
2. Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy
   Tiancheng Zhang, Chenhao Zhang, Zile Fu, Qiang Gao · 2022 · Pharmaceutics
3. Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
   Kevin Kayvan Zarrabi, Oladimeji Lanade, Daniel M. Geynisman · 2022 · Cancers
4. Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
   Maria Papathanassiou, Ioannis Tamposis, Kalliopi K. Exarchou-Kouveli, Panagiota I. Kontou, Anna Tzortzi de Paz, Lampros Mitrakas, Maria Samara, Pantelis G. Bagos, Vassilios Tzortzis, Panagiotis J. Vlachostergios · 2022 · Frontiers in Oncology
5. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
   Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2022 · Targeted Oncology
6. Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment
   Sei Hyun Park, Ryounho Eun, Janghun Heo, Yong Taik Lim · 2022 · Drug Delivery and Translational Research
7. Proteomics Characterization of Clear Cell Renal Cell Carcinoma
   Jesús Miranda, Lucía Trilla‐Fuertes, Rocío López‐Vacas, Elena López‐Camacho, Eugenia García‐Fernández, A. Pertejo, María Isabel Lumbreras-Herrera, Andrea Zapater‐Moros, Mariana Díaz‐Almirón, Antje Dittmann et al. · 2023 · Journal of Clinical Medicine
8. Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials
   Mahwish Farrukh, Muhammad Ashar Ali, Madiha Naveed, Rooma Habib, Huda Khan, Tooba Kashif, Hina Zubair, Memoona Saeed, Sigmone Khalid Butt, Rabiya Niaz et al. · 2023 · Hematology/Oncology and Stem Cell Therapy
9. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
   Matteo Rosellini, Elisa Tassinari, Andrea Marchetti, Valentina Tateo, Giacomo Nuvola, Alessandro Rizzo, Francesco Massari, Veronica Mollica · 2023 · Expert Opinion on Drug Safety
10. Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
    Tingxuan Huang, Jun Wang, Ruiqi Liu, Wensu Wei, Yang Liu, Zhiling Zhang, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He et al. · 2023 · Clinical Genitourinary Cancer
11. The role of nephrectomy in metastatic renal cell carcinoma in the immuno‐oncology era
    Christoph Würnschimmel, Luigi Nocera, Mike Wenzel, Claudia Collà Ruvolo, Zhe Tian, Pierre I. Karakiewicz · 2021 · British Journal of Urology
12. Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence
    Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari · 2021 · Immunotherapy
13. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma
    Hiroshi Kikuchi, Takahiro Osawa, Ryuji Matsumoto, Takashige Abe, Satoru Maruyama, Toru Harabayashi, Haruka Miyata, Akira Kashiwagi, Suguru Ikeshiro, Ataru Sazawa et al. · 2021 · Urologic Oncology Seminars and Original Investigations
14. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
    Alessia Mennitto, Emma Zattarin, Massimo Di Maïo, Davide Bimbatti, Ugo De Giorgi, Sebastiano Buti, Daniele Santini, Chiara Casadei, Mariella Sorarù, Carlo G. M. Messina et al. · 2021 · Expert Review of Anticancer Therapy
15. Clinical Applications of the Gut Microbiome in Genitourinary Cancers
    Charles B. Nguyen, Ulka N. Vaishampayan · 2024 · American Society of Clinical Oncology Educational Book
16. Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab
    Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel, Salih Tünbekici, Fatma Pınar Açar, Erhan Gökmen, Burçak Karaca · 2025 · Journal of Clinical Medicine
17. mRNA vaccines for prostate cancer: A novel promising immunotherapy
    Yaxiong Tang, Xianyanling Yi, Jianzhong Ai · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
18. Regulatory B cells promote the immunosuppressive microenvironment and progression of clear cell renal cell carcinoma
    Qintao Ge, Siqi Zhou, Jiahe Lu, Shiqi Ye, Aihetaimujiang Anwaier, Xi Tian, Yonghao Chen, Hailiang Zhang, Dingwei Ye, Wenhao Xu · 2024 · Immunotherapy Advances
19. Navigating liver toxicity in the age of novel oncological agents
    Mar Riveiro‐Barciela, Eléonora De Martin · 2025 · JHEP Reports
20. The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium
    André Bento‐Abreu, Saar Vandekeere, Demet Sönmez, Catarina Neves, Tyler Mantaian, Olivier Ethgen, Raquel Aguiar‐Ibáñez · 2025 · Oncology and Therapy
21. Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer
    Jiakai Hou, Cheng‐Wei Ju, Nicholas A. Egan, Yanjun Wei, Yunfei Wang, Minghao Dang, Tianyi Zhou, Leilei Shi, Ningbo Zheng, Si Chen et al. · 2025 · Advanced Science
22. Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients
    Jian Gao, Huijiu Luo, Shiyu Wang, Chao Zhou, Zhenhao Li, Chea Kimhoy, Guobiao Liang, Shulian Chen · 2025 · Journal of Translational Medicine
23. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
    Robert John Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, Cristina Suárez, Masatoshi Eto, Hernán Javier Cutuli, Camillo Porta et al. · 2026 · The Lancet
24. Nebenwirkungen der Immun-Checkpoint-Inhibitor-Therapie urologischer Tumoren
    Marc‐Oliver Grimm, Tobias Gottschlich, Nalyan Ali, Susan Foller, Katharina Leucht · 2021 · Der Urologe
25. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent
    Eddy Shih-Hsin Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta Kumar Pal et al. · 2021 · Molecular Cancer Therapeutics
26. Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
    Chunying Peng, Katrin Rabold, Willem J. M. Mulder, Martin Jaeger, Romana Teodora Netea-Maier · 2021 · Cancers
27. Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes
    Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Chris P. Miller, Scott S. Tykodi, Edus Houston Warren · 2022 · Frontiers in Oncology
28. Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
    Devayani Machiraju, Jessica C. Hassel · 2023 · Frontiers in Oncology
29. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
    Elizabeth Riley Kessler, Eryn Callihan, Junxiao Hu, Corbin Jeffrey Eule, Geetika Srivastava, Douglas Jerome Kemme, Praveena Iruku, Vishal Rana, James Moore, Steven Robert Schuster et al. · 2023 · Cancer Research Communications
30. Establishment of a pathomic-based machine learning model to predict CD276 (B7-H3) expression in colon cancer
    Jia Li, Dongxu Wang, Chenxin Zhang · 2024 · Frontiers in Oncology
31. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending
    Daniel A. Goldstein, Leonard B. Saltz, Gregory R. Pond, Ian F. Tannock · 2024 · BMJ Oncology
32. Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review
    Andrea Di Marco, Grazia Artioli, Adolfo Gino Favaretto, Nicolò Cavasin, Umberto Basso · 2024 · Medicine
33. Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
    Xiaohong Kuang, Run Xu, Jian Li · 2024 · Critical Reviews in Oncology/Hematology
34. A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling
    Melissa Dolan, Yuhao Shi, Michalis Mastri, Mark D. Long, Amber McKenery, James W. Hill, Cristina Vaghi, Sébastien Benzekry, Joseph J. Barbi, John M.L. Ebos · 2024 · Molecular Cancer Therapeutics
35. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014–2022)
    Xiayang Ren, Haijun Wang, Lei Deng, Wenqing Wang, Yanfeng Wang · 2024 · International Immunopharmacology
36. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma
    Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai et al. · 2024 · Journal of Clinical Medicine
37. Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations
    Arshit Narang, Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Gliceida Galarza Fortuna, Nicolas Sayegh, Clara Tandar, Nishita Tripathi, Beverly Chigarira et al. · 2024 · Kidney Cancer
38. Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
    Loubna Omri, Marie Naigeon, Ronan Flippot, Javier Gavira, Jesús Manuel Poveda-Ferriols, Dan J.M. Nguyen, Chaimae Abdi, Alvaro Arroyo-Salgado, Nathalie Chaput, Guillermo de Velasco et al. · 2024 · Exploration of Targeted Anti-tumor Therapy
39. Recommandations françaises du Comité de cancérologie de l’AFU – Actualisation 2024–2026 : cancer du rein
    Pierre Bigot, R. Boissier, Z. Khene, Laurence K. Albiges, Jean‐Christophe Bernhard, Jean-Michel Corréas, S. De Vergie, N. Doumerc, Matthieu Ferragu, Alexandre Ingels et al. · 2024 · Progrès en Urologie - FMC
40. KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma
    Chengyuan Dong, Ziyou Lin, Yunzhao Hu, Qun Lu · 2024 · Journal of Cancer
41. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder
    Young H. Lee, Molly M. Lee, Dinuka M. De Silva, Arpita Roy, Cara E. Wright, Tiffany K. Wong, Rene Costello, Oluwole Olaku, Robert L. Grubb, Piyush Kumar Agarwal et al. · 2021 · PLoS ONE
42. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma
    Andrew Warren Hahn, Daniel J. George, Neeraj Agarwal · 2021 · Clinical Cancer Research
43. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database
    Emre Yekedüz, İsmail Ertürk, Deniz Güncel Tural, Nuri Karadurmuş, Serdar Karakaya, Mutlu Hızal, Rukiye Arıkan, Çağatay Arslan, Hakan Taban, Ahmet Küçükarda et al. · 2021 · Future Oncology
44. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis
    Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maïo · 2021 · Immunotherapy
45. Antiangiogenic drugs: Chemosensitizers for combination cancer therapy
    Sandra Donnini, Arianna Filippelli, Valerio Ciccone, Andrea Spini, Emma Ristori, Marina Ziche, Lucia Morbidelli · 2022 · Elsevier eBooks
46. Emerging Therapies in Penile Cancer
    Antonio Machado Alencar, Guru Sonpavde · 2022 · Frontiers in Oncology
47. Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
    Johanna Noel, Anne Jouinot, Jérôme Alexandre, Guillaume Ulmann, Marie Bretagne, Zahra Castel Ajgal, Sixtine De Percin, Clémentine Villeminey, Marie‐Pierre Revel, Michaël Peyromaure et al. · 2022 · Cancers
48. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
    Emre Yekedüz, Serdar Karakaya, İsmail Ertürk, Deniz Güncel Tural, Gökhan Uçar, Nihan Şentürk Öztaş, Rukiye Arıkan, Mutlu Hızal, Ahmet Küçükarda, Özlem Nuray Sever et al. · 2022 · Clinical Genitourinary Cancer
49. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis
    Yuan Tian, Chi Zhang, Qi Dang, Kaiyong Wang, Qian Liu, Hongmei Liu, Heli Shang, Junyan Zhao, Yuedong Xu, Tong Wu et al. · 2022 · Journal of Oncology
50. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Yasser M. A. Ged, Chung‐Han Lee · 2022 · Expert Review of Anticancer Therapy
51. Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors
    Seung Eun Lee, Kyoung‐Ah Kim, Hyunjung Lee, Jinkyeong Park · 2022 · Cancer Epidemiology
52. Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report
    Arisa Machida, Daiki Ikarashi, Naoki Yanagawa, Masamichi Suzuki, Tatsuya Kawamura, Kie Sekiguchi, Kenta Takahashi, Renpei Kato, Tomohiko Matsura, Shigekatsu Maekawa et al. · 2022 · Cancer Diagnosis & Prognosis
53. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
    Hartlee Johnston, Allison Mary Deal, Katherine P. Morgan, Bianka A. Patel, Matthew I. Milowsky, Tracy L. Rose · 2023 · Clinical Genitourinary Cancer
54. Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma
    Shagnik Ray, Shawn Dason, Eric A. Singer · 2023 · Urologic Clinics of North America
55. Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors
    Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2023 · Japanese Journal of Clinical Oncology
56. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation
    Kok Hoe Chan, Ningjing Li, Ran Lador, Mark J. Amsbaugh, Anneliese O Gonzalez, Putao Cen · 2024 · Journal of Investigative Medicine High Impact Case Reports
57. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
    Brian Addis Costello, Nrupen Anjan Bhavsar, Yousef Zakharia, Sumanta Kumar Pal, Ulka N. Vaishampayan, Heather Jim, Mayer Fishman, Ana M. Molina, Christos E. Kyriakopoulos, Che‐Kai Tsao et al. · 2021 · Clinical Genitourinary Cancer
58. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma
    Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Veronica Mollica, Nicola Battelli, Francesco Massari, Matteo Santoni · 2021 · Expert Opinion on Pharmacotherapy
59. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
    Marco Maruzzo, Francesco Pierantoni, Alberto Bortolami, Dario Palleschi, Andrea Zivi, Maurizio Nicodemo, Donata Sartori, Rocco De Vivo, Fable Zustovich, Davide Bimbatti et al. · 2022 · Targeted Oncology
60. Current State of Cell Therapies for Genitourinary Malignancies
    Mohammed Alkhouli, Sarah Bazargan, Shari Pilon‐Thomas, Michael Adam Poch, Jad Chahoud · 2022 · The Cancer Journal
61. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
    Daniel Castellano, Andrea Borghese Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Pablo Maroto · 2022 · Therapeutic Advances in Medical Oncology
62. Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review
    Jeffrey Graham, Arndt Vogel, Ann‐Lii Cheng, Georg A. Bjarnason, Joel W. Neal · 2022 · Cancer Treatment Reviews
63. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
    Kosuke null Takemura, Vishal Navani, Matthew Scott Ernst, John Connor Wells, Luís Meza, Sumanta Kumar Pal, Jae‐Lyun Lee, Haoran Li, Neeraj Agarwal, Ajjai Shivaram Alva et al. · 2022 · The Journal of Urology
64. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients’ Voice or a Missed Opportunity
    Juskaran S. Chadha, Jacob J. Adashek, Heather Jim, Youngchul Kim, Adele Semaan, Nicholas Haig Chakiryan, Houssein Safa, Ali J. Hajiran, Wade Jeffers Sexton, Scott Michael Gilbert et al. · 2021 · Clinical Genitourinary Cancer
65. Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
    Viktor Grünwald, Lothar Bergmann, Bernhard Brehmer, B. Eberhardt, Karin Kastrati, Thomas Christoph Gauler, G. Gehbauer, Jürgen E. Gschwend, Manfred Johannsen, T. Klotz et al. · 2022 · World Journal of Urology
66. The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis
    Ge Song, Song Xue, Yingming Zhu, Chunling Wu, Xiaowei Ji · 2024 · BMC Pharmacology and Toxicology
67. Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
    Mehul Gupta, Connor Wells, Meredith M. Regan, Wanling Xie, Vishal Navani, Renée Maria Saliby, Naveen S. Basappa, Frede N. Donskov, Takeshi Yuasa, Kosuke null Takemura et al. · 2024 · European Urology Oncology
68. Decoding driver and phenotypic genes in cancer: Unveiling the essence behind the phenomenon
    Dequan Liu, Lei Liu, Xiaoman Zhang, Xinming Zhao, Xiaorui Li, Xiangyu Che, Guangzhen Wu · 2025 · Molecular Aspects of Medicine
69. Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)
    Javier Gavira, Édouard Auclin, Macarena Rey-Cárdenas, Pritha Roy, José Carlos Tapia, Paula Nay, Armelle Vinceneux, Félix Lefort, Simon Nannini, Adela Maria del Carmen Randis et al. · 2025 · European Journal of Cancer
70. Current Evidences and Future Perspectives in the Management of Metastatic Non‐Clear Cell Renal Cell Carcinoma
    Shotaro Nakanishi, Junichi Inokuchi · 2025 · International Journal of Urology
71. Advances in renal cancer: diagnosis, treatment, and emerging technologies
    Tsukasa Saida, Mami Iima, Rintaro Ito, Daiju Ueda, Kentaro Nishioka, Ryo Kurokawa, Mariko Kawamura, Kenji Hirata, Maya Honda, Koji Takumi et al. · 2025 · La radiologia medica
72. Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
    Akash Sabarwal, Marc Machaalani, Laxminarayan Rawat, Johannes Wedel, Saba Tabasum, Yuzuru Sasamoto, Florian Buerger, Josie Ascione, Marc Eid, Karl Semaan et al. · 2025 · Cancer Letters
73. Reviewing the Current State of Renal Cell Carcinoma with a Tumor Thrombus: Epidemiology, Pathophysiology, Metastasis, and Systemic Therapy
    Maxwell Louis Sandberg, Randall G. Bissette, Kimberly Waggener, Gaetano Ciancio, Alejandro R Rodriguez · 2025 · Current Urology Reports
74. CAR-T cell therapy for solid tumors: HIF-1α as a potential enhancement strategy
    Hai Li, Jie Xiong, Chun hui Wang, Li bing Hu, Ying bao Wang, Qin rong Ping, Meng Yang, Jun Tan, Ting Li, Yang Yang · 2025 · Autoimmunity
75. Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study
    Taigo Kato, Yasutomo Nakai, Mototaka Sato, Tetsuya Takao, Toshichika Iwanishi, Shingo Toyoda, Hiroki Osaki, Masao Tsujihata, Koichi Okada, Ken‐ichi Kakimoto et al. · 2025 · Scientific Reports
76. KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model
    Chad Z. Tang, Aaron Seo, Alexander Dean Sherry, Peng Yang, Kieko Hara, Kanishka Sircar, Giannicola Genovese, Eric W. Jonasch, Amishi Yogesh Shah, Amado J. Zurita et al. · 2026 · European Urology
77. Dual immune checkpoint blockade strategies for cancer therapy
    Ying Liu, Umesh Prasad Yadav, Cunte Chen, Peipei Wang · 2026 · Cell investigation.
78. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
    Qing Wu, Shuimei Luo, Xianhe Xie · 2022 · Journal of Immunotherapy
79. What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy
    Patricia J. Zondervan, Axel Bex · 2022 · Kidney Cancer
80. A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
    Hiroaki Sato, Tomokazu Sazuka, Ayumi Fujimoto, Sakurako Kagitani, Takayuki Arai, Yusuke Goto, Yusuke Imamura, Shinichi Sakamoto, Jun‐ichiro Ikeda, Tomohiko Ichikawa · 2023 · IJU Case Reports
81. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
    Regina Barragán-Carrillo, Ameish Govindarajan, Adam G. Rock, Rubens Copia Sperandio, Sumanta Kumar Pal · 2023 · Hematology/Oncology Clinics of North America
82. Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019
    Samantha Conroy, James W.F. Catto, Axel Bex, Janet Elizabeth Brown, Jon J. Cartledge, Alison Fielding, Robert J. Jones, Vincent S Khoo, David L. Nicol, Grant Duncan Stewart et al. · 2023 · British Journal of Urology
83. Antigenic targets in clear cell renal cell carcinoma
    Nicholas R. Schindler, David A. Braun · 2023 · Kidney Cancer
84. Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region
    Zachariah Thomas, Prashant Jambunathan, Anjali Mary Jibi, Ajoy Oommen John, Ashish Singh · 2023 · BMJ Case Reports
85. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
    İzzet Doğan, Ayça İribaş, Nail Paksoy, Sezai Vatansever, Mert Başaran · 2023 · Journal of Cancer Research and Therapeutics
86. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis
    Shan Wang, Hongwei Lv, Jing Yu, Miao Chen · 2024 · International Immunopharmacology
87. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
    Siwei Yang, Xianrui Yang, Zekai Hou, Liang Zhu, Zhili Yao, Yifei Zhang, Yanzhuo Chen, Jie Teng, Cheng Fang, Songmao Chen et al. · 2024 · Heliyon
88. Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study
    Tokiyoshi Tanegashima, Masaki Shiota, Nobuhiro Fujiyama, Shintaro Narita, Tomonori Habuchi, Genshiro Fukuchi, Dai Takamatsu, Yoshinao Oda, Hideaki Miyake, Masayuki Takahashi et al. · 2024 · The Journal of Immunology
89. Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma
    Nanaka Katsurayama, Hiroki Ishihara, Ryo Ishiyama, Yuki Nemoto, Takashi Ikeda, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka et al. · 2024 · Cancer Diagnosis & Prognosis
90. Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications
    Francesco Ditonno, Eugenio Bologna, Leslie Claire Licari, Antonio Franco, Greta Pettenuzzo, Costantino Leonardo, Flavia Proietti, Umberto Carbonara, Maria Carmen Mir, Simone Crivellaro et al. · 2024 · World Journal of Urology
91. Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy
    J.C. Angulo, Gorka Larrinaga, David Lecumberri, Ane Miren Iturregui, Jon Danel Solano-Iturri, Charles Henderson Lawrie, María Armesto, Juan F. Dorado, Caroline E. Nunes‐Xavier, Rafael Pulido et al. · 2024 · Cancers
92. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab
    Yana Beulque, Lisa Kinget, Eduard Roussel, Sajedeh Mobaraki, Annouschka Laenen, Philip R. Debruyne, Yannick Van Herck, Marcella M.L.L. Baldewijns, Agnieszka Woźniak, Abhishek Dinkarnath Garg et al. · 2024 · Acta Oncologica
93. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer
    Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Tomoo Itoh, Masanori Teshima, Ken‐ichi Nibu, Kazuko Sakai et al. · 2024 · Asia-Pacific Journal of Clinical Oncology
94. Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis
    Alessandro Rizzo, Fernando Sabino Marques Monteiro, Veronica Mollica, Andrey Soares, Oronzo Brunetti, Angela Dalia Ricci, Francesco Massari, Matteo Santoni · 2024 · Clinical & Experimental Metastasis
95. Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
    Wendy J. Li, Wisam O. Najdawi, Omar Badla, Anat Galor, Carol L. Karp · 2025 · Seminars in Ophthalmology
96. AO Spine Clinical Practice Recommendations: Current Systemic Oncological Treatments with the Largest Impact on Patients with Metastatic Spinal Disease
    Marcin Czyż, G. Emerens Wensink, Brian Guilherme Monteiro Marta Coimbra, Michael Anthony Galgano, SHREYASKUMAR R. PATEL, Kristin Janson Redmond, Joost P. H. J. Rutges, Jiong Hao Tan, Ori Barzilai, Nicolas Dea et al. · 2025 · Global Spine Journal
97. STARLITE 1: Phase 1b/2 Study of Combined 177Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma
    Elshad Hasanov, Lesley Flynt, Rebecca S. Slack Tidwell, Hyunsoo Hwang, Roserika Brooks, Lauren Michelle Wood, Travis N. Solley, Mashaal Syed, Aradhana M. Venkatesan, Eric Jonasch · 2025 · European Urology Focus
98. JS-K induces ferroptosis in renal carcinoma cells by regulating the c-Myc-GSTP1 Axis
    Yuwan Zhao, LuGang Zhu, Xinghua Lin, Bin Li, Bailiang Miu, Jingping Qiu, Sheng Gao, Jianjun Liu · 2025 · Scientific Reports
99. The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies
    Vinay K. Giri, David F. McDermott, Jacob Peter Zaemes · 2025 · Cancer
100. Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma
     Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu · 2022 · Clinical Cancer Research